加强看多保健品：新消费新机遇，个股逻辑鲜明 20250515 摘要 • 保健品行业呈现结构性增长，2017-2022 年复合增长率为 5%，虽增速中 低，但新消费趋势下机遇涌现，如仙乐健康通过业务转型实现盈利增长， 估值提升。 • 盐津铺子受益于量贩零售渠道，尽管市场对其增速存疑虑，但长期增长潜 力仍被看好。其利润率虽短期回落，但符合大单品逻辑，在新渠道和消费 场景表现出色。 • 新消费公司涉足保健品领域，通过销售快速增长驱动业绩，个股逻辑凸显。 仙乐健康等企业通过业务转型和剥离亏损业务，实现了盈利并提高了估值。 • 保健品行业具潜力，类似几年前的蓝筹股，有重新任职机会。新品牌需拥 抱新消费路径，挖掘保健品新消费属性，通过渠道合作扩大影响力，如新 健康与 JMC 直播等合作。 • 燕之初作为燕窝代工龙头，具备采购优势和技术积累，拥有 2000 家客户 及 70 项专利。若能打通 C 端市场，实现从代工向品牌转型，估值有望提 升。 Q&A 保健品行业的现状及未来发展趋势如何？ 保健品行业在内需和食品饮料的各个细分领域中算是挖掘较晚的一个洼地。近 年来，随着若羽臣等公司的涉足，保健品行业的关注度显著提升。我们建议 ...

据《中国食品药品监管》杂志2024年8月30日发布的《麦角硫因的功能、制备及应用研究进展》，麦角硫因是一种天然的小分子组氨酸硫脲衍生物，存在于 微生物细胞和动植物体内。EGT可由真菌、蓝细菌、放线菌等微生物合成，人体自身不能合成EGT，需通过饮食摄取，食用菌是EGT的重要饮食来源之一。 一、行情回顾 市场全天缩量调整，创业板指尾盘跌近2%。合成生物概念逆势大涨，川宁生物、洁雅股份、美农生物等多股涨停。航运板块冲高回落，宁波海运、宁波远 洋、连云港等均三连板。食品、服装、美容护理等消费股活跃，西王食品、拉芳家化、凤竹纺织等涨停。下跌方面，军工板块调整，天箭科技接近跌停；算 力概念股走弱，宏景科技跌近10%。个股跌多涨少，沪深京三市超3800股飘绿，今日成交1.19万亿。 二、当日热点 1.保健品 消息上，近日，科伦药业一则麦角硫因胶囊广告引发热议，公司董事长刘革新亲自上阵担任产品代言人，视频中其裸露上半身，肌肉线条肌理分明充满力 量。 | 股票名称 | | 最新价 = | 涨跌幅 = | 涨停时间◆ | 换手率( | 流通市值 = | | | --- | --- | --- | --- | --- | --- ...

智通财经5月15日电，大消费概念持续走强，日化、保健品、宠物经济等新消费方向领涨，午后华业香 料、百洋股份涨停，此前金达威、西王食品、交大昂立、若羽臣涨停，青松股份、中草香料、仙乐健 康、丸美生物等涨幅靠前。消息面上，机构指出，当前，国内新消费企业增长强劲，在审美、精神满足 上的升级持续存在，以潮玩、IP文化、宠物等为主的"情感"消费、"体验"消费景气度更是持续上升。 大消费概念持续走高 华业香料等多股涨停 ...

智通财经APP获悉，天风证券发布研报称，白酒五一宴席场景表现积极，25年磨底阶段酒企普遍 求"稳"，建议关注后续消费刺激政策出台为板块带来的估值修复机会，淡季核心高端酒批价表现或为板 块趋势变化催化剂。啤酒与饮料方面，五一出行数据超预期，统一Q1高增，带动板块行情。保健品涨 幅居前，看好潜在顺周期下三大投资主体机会。 港股食饮建议关注：统一(00220)、康师傅(00322)、青啤H(00168)、华润啤酒(00291)、百威(01876)、蒙 牛乳业(02319)、卫龙美味(09985)、悠然牧业等。 白酒板块推荐α相对强&享受一定价位β红利的白酒龙头酒企：①强α主线：山西汾酒(600809.SH)/今世缘 (603369.SH)/贵州茅台(600519.SH)等；②顺周期β主线：泸州老窖(000568.SZ)/酒鬼酒(000799.SZ)/水井坊 (600779.SH)/舍得酒业(600702.SH)等。 大众品方面重点推荐零食/休闲食品板块。25年大众品或将成为具有强弹性赛道，建议关注：①"休闲食 品"条线：西麦食品(002956.SZ)/五芳斋(603237.SH)/卫龙美味/三只松鼠(300783. ...

智通财经APP获悉，5月13日，中国医药保健品进出口商会发布2025年一季度我国医药外贸情况简报。2025年一季度，中国医药保健品进出口贸易在复杂 多变的国际环境中展现出"总量平稳、结构优化"的特征。进出口总额达到470.88亿美元，同比微增0.38%。其中，出口额为266.32亿美元，同比增长 4.39%，主要依赖西药原料、医疗器械耗材等传统优势产品的持续增长；进口额则延续收缩态势，同比下降4.42%至204.56亿美元，反映国内产业升级带来 的进口替代效应。 从结构看，西药类产品以256.05亿美元占据54.4%的份额，仍是主导品种，其中西药原料出口111.08亿美元，同比增长5.19%，激素类、维生素类等细分品 类表现亮眼，但呼吸系统用药、青霉素类等受国际竞争加剧影响出现下滑。医疗器械产品以195.61亿美元占比41.5%，同比增长5.38%，一次性耗材、医用 敷料等低附加值产品仍是出口主力，而高端设备进口替代加速，医院诊断与治疗设备进口下降7.01%。中药类进出口额19.43亿美元，同比下滑3.42%，提 取物出口7.83亿美元，增长9.35%。 出口市场呈现日趋多元化格局。美国作为最大单一市场，对美 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for 2024 and Q1 2025, indicating challenges in its operational performance and market conditions [1][2]. Financial Performance - Total revenue for 2024 was 6.838 billion yuan, a decrease of 27% year-on-year, with a net profit of 653 million yuan, down 63% [1]. - In Q4 2024, total revenue was 1.105 billion yuan, a decline of 32%, with a net loss of 216 million yuan compared to a loss of 155 million yuan in Q4 2023 [1]. - For Q1 2025, total revenue was 1.792 billion yuan, down 32%, with a net profit of 455 million yuan, a decrease of 37% [1]. Margin Analysis - Gross margin for 2024 and Q1 2025 decreased by 2 percentage points and 1 percentage point to 66.69% and 68.66%, respectively, primarily due to changes in product mix and reduced scale effects [1]. - The net profit margin decreased by 9 percentage points and 1 percentage point to 9.47% and 26.04%, respectively, with expectations of gradual improvement in profitability through better cost control [1]. Product Strategy - In 2024, revenue from tablets, powders, and capsules was 1.049 billion yuan, 625 million yuan, and 1.103 billion yuan, reflecting declines of 41%, 42%, and 26%, respectively [2]. - The company is piloting a new low-cost, high-volume model for its calcium product, which has exceeded expectations, with plans to launch new products under this model in Q2 2025 [2]. Channel Strategy - Revenue from online and offline channels in 2024 was 1.222 billion yuan and 3.125 billion yuan, down 28% and 32%, respectively [2]. - The company is enhancing the differentiation between online and offline products, focusing on consumer benefits and increasing the proportion of high-end online offerings [2]. Earnings Forecast - The company is adjusting its task allocation to smooth out quarterly fluctuations and expects gradual release of scale effects [3]. - EPS forecasts for 2025-2027 are 0.46, 0.52, and 0.59 yuan, with corresponding PE ratios of 24, 21, and 19 times [3].

Core Viewpoint - The recent advertisement featuring Kelong Pharmaceutical's chairman, Liu Gexin, showcasing his physique at the age of 75 has sparked discussions, with mixed opinions from the public regarding its authenticity and effectiveness compared to celebrity endorsements [1][4]. Summary by Sections Advertisement and Product Promotion - Liu Gexin, the chairman of Kelong Pharmaceutical, promotes the company's ergothioneine capsules, emphasizing their potential anti-aging benefits and claiming that the product's effectiveness in eliminating free radicals is 10-30 times greater than traditional ingredients like Vitamin C and Coenzyme Q10 [5]. - The capsules are priced at 1499 yuan for a bottle containing 60 capsules, and the advertisement has passed regulatory review, set to be broadcast soon [5]. Product Background and Market Potential - Ergothioneine is a rare amino acid with antioxidant, cell protection, and anti-inflammatory properties, showing promise in disease prevention and treatment, including neuroprotection and potential benefits for sleep and memory enhancement [8]. - The product is relatively uncommon in oral form, with more prevalence in skincare products [8]. Financial Performance - Kelong Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.39 billion yuan, and a 43.07% drop in net profit to 584 million yuan [10]. - The company's core infusion business continues to face challenges due to centralized procurement policies, leading to a significant revenue decline in its synthetic biology segment [10]. Strategic Direction - In light of declining financial performance, Kelong Pharmaceutical is venturing into the health and wellness sector, with Liu Gexin personally endorsing the high-end health products as a strategy to create a new growth avenue [12]. - Kelong Yongnian, a subsidiary focused on health products, was established in 2024 and is fully controlled by Kelong Pharmaceutical [12]. Leadership and Market Position - Liu Gexin, known as the "King of Infusion," has significant influence in the industry, with Kelong Pharmaceutical holding a leading market share of 22.1% in the infusion market as of 2008 [15]. - The chairman's family controls three publicly listed companies, with a combined market value exceeding 549 billion yuan [13]. Industry Trends - The trend of entrepreneurs endorsing their own products is becoming more common, with examples including Vanke's Wang Shi and Gree's Dong Mingzhu, indicating a shift towards personal branding in marketing strategies [16].

Group 1 - The company will hold its 2024 Annual General Meeting on May 20, 2025, at 14:30, with both on-site and online voting options available [1][2] - The meeting agenda includes the reading of the meeting notice, discussion of proposals, shareholder speeches, and voting procedures [2][3] - There are 9 proposals to be voted on, requiring more than half of the voting rights held by attending shareholders for approval [4] Group 2 - The company reported a net profit of 30.48 million yuan for 2024, marking a turnaround from previous losses, with total assets of 758.88 million yuan and net assets of 325.71 million yuan [5] - The board of directors has organized two shareholder meetings during the reporting period, addressing various reports and proposals [6][7] - The board held 9 meetings, discussing topics such as executive compensation and the election of board members [8][9] Group 3 - The supervisory board held 6 meetings, reviewing the company's financial reports and ensuring compliance with legal regulations [26][31] - The supervisory board confirmed that the company operates in accordance with laws and regulations, with no violations reported [32] - The company has established a sound internal control system, with audits confirming compliance and effectiveness [35] Group 4 - The company plans to distribute a cash dividend of 0.118 yuan per share for the 2024 fiscal year, totaling approximately 9.14 million yuan, which is 30% of the net profit [40] - The company has outlined its expected related party transactions for 2024 and 2025, with a total estimated amount of 74.5 million yuan for various services [42][43] - The company has implemented measures to manage insider information and ensure compliance with disclosure regulations [22][36]

[Table_Tag] 宏观策略 证券研究报告 东吴证券晨会纪要 东吴证券晨会纪要 2025-05-09 宏观点评 20250508：关税迷雾深，联储降息更难择机——2025 年 5 月 FOMC 会议点评 核心观点：5 月 FOMC 上美联储如期维持利率水平不变。发布会中 Powell 表达了对经济前景更大不确定性与滞胀风险的担忧，同时 Powell 也表示 关税带来的滞胀风险让美联储在就业与通胀目标中的抉择将更具挑战 性，这意味着美联储择机降息难度将更大，对待货币政策也将采取更加谨 慎的的态度，因此当前市场计价的全年 3 次降息预期面临进一步向下修 正的风险。 风险提示：特朗普政策落地节奏与预期相差较大；美联储维 持高利率水平时间过长，引发金融系统流动性危机；通胀下行速率不及预 期。 [宏观深度报告 Table_MacroStrategy] 20250508：基于 38 个国家的比较：为何我国消费率偏低 我国居民可支配收入比重高于国际平均、消费倾向低于国际平均，是否说 明我国居民部门"有钱不愿花"？并非如此，由于个税和财产税主要影响 少数中高收入者，因此剔除中高收入者后，对大多数居民而言，我国跟其 他国家 ...

4月25日，民生健康发布年报，2024年实现营业收入6.41亿元，同比增长10.23%；实现归母净利润9183.41万元，同比增长7.24%；实现扣非净利润8720.93万 元，同比增长10.13%；基本每股收益为0.26元/股。 2024年，民生健康毛利率为55.77%，同比下降6.30个百分点；净利率为14.32%，同比微降0.40个百分点；销售费用为1.91亿元，同比增长0.32%，主要为投入 渠道维护与品牌推广；研发费用为2398.05万元，同比下降18.87%，占营收的3.74%。 现金流方面，2024年民生健康经营活动现金流净额为1.08亿元，同比微增0.28%，经营回款能力稳定；投资活动现金流净流出2.80亿元，同比上升45.53%， 主要用于募投项目及理财产品购置；筹资活动现金流量净额为-3834万元，同比下降104%。 分业务看，2024年民生健康维生素与矿物质收入为6.21亿元，同比增长10.47%，占比为96.91%；其他保健品收入为0.12亿元，同比增长8.01%，占比为 1.93%；益生菌收入为422万元，同比下降33.74%,占比为0.66%。 2024年，民生健康取得新增授权发明 ...